Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated at JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report issued on Monday,Benzinga reports. The firm set an “overweight” rating and a $20.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 103.05% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald raised their target price on Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Truist Financial upped their target price on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. The Goldman Sachs Group reaffirmed a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Finally, Bank of America boosted their price target on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.11.

Fulcrum Therapeutics Trading Down 2.6%

FULC stock opened at $9.85 on Monday. The stock’s 50 day simple moving average is $10.69 and its 200 day simple moving average is $8.77. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74. The firm has a market cap of $533.06 million, a P/E ratio of -8.35 and a beta of 3.20.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, research analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director owned 469,864 shares in the company, valued at approximately $5,577,285.68. This represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 4,205,139 shares of company stock worth $58,711,943 in the last 90 days. 7.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. boosted its stake in shares of Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock valued at $31,572,000 after buying an additional 1,589,000 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth $9,207,000. Invesco Ltd. lifted its stake in shares of Fulcrum Therapeutics by 448.4% in the 2nd quarter. Invesco Ltd. now owns 470,333 shares of the company’s stock valued at $3,236,000 after purchasing an additional 384,566 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in Fulcrum Therapeutics by 8.9% during the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after buying an additional 382,485 shares in the last quarter. Finally, Boothbay Fund Management LLC raised its stake in shares of Fulcrum Therapeutics by 104.2% in the 3rd quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after acquiring an additional 346,136 shares in the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.